Cholesterol’s Silent Threat: New Guidelines Demand Earlier Vigilance

A pivotal clinical guideline concerning the assessment and management of blood cholesterol levels, first issued by the American College of Cardiology and the American Heart Association in 2018, has undergone its inaugural revision. This updated guidance, jointly published in the esteemed journals Journal of the American College of Cardiology and Circulation, is slated for comprehensive discussion during the American College of Cardiology’s 75th Annual Scientific Session in New Orleans on March 28.

The dissemination of this updated guideline closely followed the publication of a related paper, “The ABCs of Cardiovascular Disease Prevention: Communicating What We Know in 2026,” which appeared in the American Journal of Preventive Cardiology. The core focus of the new recommendations centers on strategies to reduce elevated levels of low-density lipoprotein (LDL) cholesterol, commonly known as “bad” cholesterol, alongside other circulating lipid fractions such as lipoprotein(a) or Lp(a). A significant emphasis is placed on initiating cholesterol screenings at an earlier age, particularly for individuals with a predisposition to heart disease due to family history, and on adopting more individualized risk stratification methods. This personalized approach, accounting for pre-existing medical conditions, is designed to foster collaborative decision-making between healthcare providers and their patients.

It is well-established that diminished LDL cholesterol concentrations are instrumental in mitigating the risk of myocardial infarction, cerebrovascular accidents, and congestive heart failure. Furthermore, effective management of elevated lipids and hypertension in young adults contributes to enduring cardiac and vascular well-being throughout an individual’s lifespan.

Roger S. Blumenthal, M.D., chairman of the guideline drafting committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease

This revised guidance emerges amidst evidence indicating that one in every four adults in the United States exhibits elevated LDL cholesterol (LDL-C), a significant contributor to atherosclerosis, a condition characterized by the narrowing and hardening of arterial pathways. The excessive accumulation of specific lipids can accelerate the formation and progression of arterial plaque. Compromised atherosclerotic plaque within the coronary arteries can impede blood flow. External factors, such as advanced age and other cardiovascular risk elements, can destabilize plaque, potentially leading to heart attacks, strokes, or the imperative for immediate interventions to re-establish circulation.

Dr. Blumenthal stresses that the fundamental tenets of promoting cardiac health and maintaining cholesterol within optimal parameters remain constant. These include adherence to a heart-conscious diet, consistent engagement in vigorous physical activity, abstinence from tobacco products, ensuring adequate sleep, and maintaining a healthy body mass. He highlights that the vast majority, approximately 80% to 90%, of cardiovascular disease is at least partially attributable to modifiable risk factors, underscoring the primacy of lifestyle interventions as an initial or foundational strategy. A notable shift in the updated cholesterol guideline involves advocating for earlier initiation of screenings and a more comprehensive assessment of risk. This enhanced assessment includes considering an individual’s family history of atherosclerosis, the presence of underlying medical conditions (such as rheumatoid arthritis), and lifetime risk factors like premature menopause or specific pregnancy complications (e.g., preeclampsia or gestational diabetes) to inform treatment strategies.

For instance, the new directive suggests that individuals with a history of familial hypercholesterolemia, an inherited condition causing exceedingly high LDL-C levels, should now undergo earlier screening, commencing in childhood around the age of nine, or even sooner. The guideline also proposes a single screening for Lp(a) levels, a factor frequently linked to genetic predisposition that can elevate cardiovascular risk by approximately 40% at concentrations of 125 nanomoles per liter and double the risk at 250 nanomoles per liter. Another enhancement is the adoption of a novel risk calculator for estimating 10- and 30-year risks of myocardial infarction and stroke. Previously, the pooled cohort equation was employed for forecasting 10-year cardiovascular disease risk in individuals aged 40 and above, incorporating baseline factors like age, cholesterol levels, and blood pressure. The updated calculator, christened Predicting Risk of Cardiovascular Disease EVENTs (PREVENT), integrates supplementary data, including indicators of glycemic control and renal function, to refine these risk projections. Its use is recommended for individuals starting at age 30. The PREVENT score is derived from data encompassing 6.6 million individuals, a substantial increase from the 26,000 individuals upon whom the prior calculator was based.

“Transitioning towards proactive preventive strategies at an earlier stage of life holds the potential to significantly alter the course of cardiovascular disease progression, ultimately yielding superior health outcomes for individuals over subsequent decades,” states Seth Martin, M.D., M.H.S., a cardiologist and member of the guideline writing committee, who also directs the Advanced Lipid Disorders Program and Digital Health Lab at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.

To further facilitate personalized risk evaluation, the guideline provides a framework for clinicians to incorporate “risk enhancers” associated with atherosclerosis.

For example, in cases where an individual presents with borderline to intermediate risk for atherosclerosis, healthcare providers may opt for supplementary diagnostic tests to guide treatment decisions. These can include quantifying the presence of systemic inflammation in the bloodstream, measured by high-sensitivity C-reactive protein (hsCRP). Elevated Lp(a) levels may also be considered, along with other pertinent factors such as a familial history of premature cardiovascular events and genetic ancestry indicative of higher risk. In addition to these risk enhancers, the revised guideline offers multiple recommendations for the utilization of coronary artery calcium scanning. This imaging technique identifies calcified deposits within the arteries, serving as an indicator of plaque burden and aiding in the personalization of therapeutic strategies.

The updated guidance also addresses treatment considerations for specific populations, including pregnant or lactating women, individuals aged 75 and older, those managing chronic conditions like diabetes, advanced chronic kidney disease, and HIV infection, as well as patients undergoing oncological therapy.

The new guideline delineates approaches to statin therapy and offers updated information on alternative lipid-lowering agents, such as ezetimibe, bempedoic acid, and injectable PCSK9 monoclonal antibody treatments. The latter class of medications is recommended for individuals who may not achieve optimal LDL-C reduction with statins alone, or who require combination therapy to attain their lipid goals.

For individuals without established cardiovascular disease, optimal LDL-C levels are generally considered to be below 100 mg/dL. The revised guideline now advises individuals categorized as having intermediate risk to achieve LDL-C levels below 70 mg/dL. Those deemed to be at higher risk are recommended to target LDL-C concentrations below 55 mg/dL. Beyond LDL-C targets, the guideline provides specific recommendations for non-HDL-C and apolipoprotein B, a protein component of cholesterol-carrying particles.

In an accompanying editorial, Dr. Blumenthal and the vice-chair of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline project anticipate that future iterations of the guidelines will likely advocate for an LDL-C target below 55 mg/dL for individuals with at least moderate atherosclerotic burden. The 2026 guideline was conceptualized prior to the release of findings from the VESALIUS-CV clinical trial, published in the New England Journal of Medicine. This trial demonstrated the efficacy of targeting these lower LDL-C ranges through combination lipid-lowering therapies.

The 2026 Guideline on the Management of Dyslipidemia represents a collaborative effort by the American College of Cardiology and the American Heart Association Joint Committee on Clinical Practice Guidelines. It has garnered endorsement and was developed in conjunction with numerous professional organizations, including the American Association of Cardiovascular and Pulmonary Rehabilitation, the Association of Black Cardiologists, the American College of Preventive Medicine, the American Diabetes Association, the American Geriatrics Society, the American Pharmacists Association, the American Society for Preventive Cardiology, the National Lipid Association, and the Preventive Cardiovascular Nurses Association.

Dr. Blumenthal served as the chair of the guideline writing committee, while Dr. Martin was a member. Additional contributors to the writing committee include Morris P.B., Gaudino M., Johnson H.M., Anderson T.S., Bittner V.A., Blankstein R., Brewer L.C., Cho L., de Ferranti S.D., Gianos E., Gluckman T.J., Gradney K., Isiadinso I., Lloyd-Jones D.M., Marrs J.C., McLain K.H., Mehta L.S., Mora S., Mulugeta W.M., Natarajan P., Navar A.M., Orringer C.E., Polonsky T.S., Reynolds H.R., Saseen J.J., Shapiro M.D., Soffer D.E., Tynes S.A., Villavaso C.D., Virani S.S., and Wilkins J.T.

Dr. Martin has disclosed prior research collaborations with Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Kaneka Pharma, Merck, NewAmsterdam Pharma, Novartis, and Sanofi, as well as an ownership stake in Corrie Health. Dr. Blumenthal and the majority of the writing committee reported no industry affiliations.